 Shawn McCandless
Concepts (392)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neonatal Screening | 12 | 2020 | 164 | 2.400 |
Why?
| | Prader-Willi Syndrome | 8 | 2024 | 27 | 2.250 |
Why?
| | Urea Cycle Disorders, Inborn | 16 | 2020 | 23 | 2.080 |
Why?
| | Phenylbutyrates | 12 | 2020 | 22 | 1.270 |
Why?
| | Metabolism, Inborn Errors | 6 | 2021 | 40 | 1.140 |
Why?
| | Glycerol | 11 | 2020 | 87 | 1.130 |
Why?
| | Hyperphagia | 4 | 2024 | 33 | 0.880 |
Why?
| | Abnormalities, Multiple | 6 | 2013 | 178 | 0.850 |
Why?
| | Phenylketonurias | 3 | 2023 | 12 | 0.790 |
Why?
| | Ammonia | 9 | 2020 | 62 | 0.770 |
Why?
| | Infant, Newborn | 28 | 2022 | 5740 | 0.690 |
Why?
| | Glutamine | 9 | 2018 | 94 | 0.690 |
Why?
| | Chromosome Deletion | 4 | 2010 | 102 | 0.630 |
Why?
| | Galactosemias | 1 | 2019 | 15 | 0.610 |
Why?
| | Cinnamates | 1 | 2017 | 9 | 0.570 |
Why?
| | Aminopeptidases | 1 | 2017 | 14 | 0.560 |
Why?
| | Cyclohexanes | 1 | 2017 | 21 | 0.560 |
Why?
| | Appetite Depressants | 1 | 2017 | 16 | 0.560 |
Why?
| | Epoxy Compounds | 1 | 2017 | 32 | 0.560 |
Why?
| | Sesquiterpenes | 1 | 2017 | 52 | 0.550 |
Why?
| | Acidosis | 1 | 2017 | 88 | 0.540 |
Why?
| | Protease Inhibitors | 1 | 2017 | 104 | 0.530 |
Why?
| | Genetic Testing | 4 | 2023 | 428 | 0.520 |
Why?
| | Lysosomal Storage Diseases | 1 | 2015 | 4 | 0.500 |
Why?
| | Glycoproteins | 1 | 2017 | 337 | 0.480 |
Why?
| | Public Health | 1 | 2020 | 482 | 0.480 |
Why?
| | Hyperammonemia | 4 | 2020 | 16 | 0.460 |
Why?
| | Infant | 25 | 2024 | 9001 | 0.450 |
Why?
| | Parenteral Nutrition | 1 | 2015 | 104 | 0.440 |
Why?
| | Consanguinity | 1 | 2013 | 47 | 0.420 |
Why?
| | Child, Preschool | 27 | 2024 | 10487 | 0.420 |
Why?
| | Hazardous Substances | 1 | 2012 | 11 | 0.400 |
Why?
| | Lipid Metabolism, Inborn Errors | 1 | 2012 | 19 | 0.400 |
Why?
| | Oligonucleotide Array Sequence Analysis | 2 | 2013 | 757 | 0.380 |
Why?
| | Obesity | 2 | 2017 | 2864 | 0.380 |
Why?
| | Amino Acids | 1 | 2015 | 477 | 0.370 |
Why?
| | Humans | 72 | 2024 | 128495 | 0.350 |
Why?
| | Phenylalanine | 4 | 2023 | 65 | 0.340 |
Why?
| | Rare Diseases | 5 | 2019 | 100 | 0.320 |
Why?
| | Child | 30 | 2024 | 20805 | 0.320 |
Why?
| | Phenylacetates | 4 | 2020 | 9 | 0.290 |
Why?
| | Attitude of Health Personnel | 1 | 2015 | 1090 | 0.290 |
Why?
| | Adolescent | 22 | 2024 | 20304 | 0.280 |
Why?
| | Acyl-CoA Dehydrogenases | 2 | 2024 | 11 | 0.270 |
Why?
| | Feeding Behavior | 1 | 2012 | 619 | 0.270 |
Why?
| | Polymorphism, Single Nucleotide | 3 | 2013 | 2064 | 0.270 |
Why?
| | Male | 40 | 2024 | 63043 | 0.260 |
Why?
| | Female | 42 | 2024 | 68266 | 0.260 |
Why?
| | Acidosis, Lactic | 2 | 2024 | 45 | 0.250 |
Why?
| | Young Adult | 15 | 2024 | 12349 | 0.250 |
Why?
| | Chromosomes, Human, Pair 3 | 1 | 2005 | 48 | 0.240 |
Why?
| | Infant Formula | 2 | 2018 | 74 | 0.230 |
Why?
| | Chromosomes, Human, Pair 21 | 1 | 2005 | 43 | 0.230 |
Why?
| | Mutation | 8 | 2019 | 3696 | 0.230 |
Why?
| | Methionine | 2 | 2021 | 157 | 0.230 |
Why?
| | Bezafibrate | 1 | 2024 | 9 | 0.230 |
Why?
| | Pyridinium Compounds | 1 | 2024 | 24 | 0.220 |
Why?
| | Trisomy | 1 | 2005 | 77 | 0.220 |
Why?
| | Diazoxide | 1 | 2024 | 23 | 0.220 |
Why?
| | False Positive Reactions | 2 | 2015 | 113 | 0.220 |
Why?
| | Neutropenia | 2 | 2022 | 134 | 0.220 |
Why?
| | Niacinamide | 1 | 2024 | 73 | 0.220 |
Why?
| | Growth Disorders | 2 | 2019 | 80 | 0.220 |
Why?
| | Vitamin B 12 | 2 | 2021 | 122 | 0.220 |
Why?
| | Genetic Diseases, Inborn | 1 | 2003 | 38 | 0.220 |
Why?
| | Delayed-Action Preparations | 1 | 2024 | 170 | 0.210 |
Why?
| | Face | 2 | 2020 | 165 | 0.200 |
Why?
| | Mass Spectrometry | 3 | 2004 | 663 | 0.200 |
Why?
| | Glycogen Storage Disease Type I | 1 | 2022 | 5 | 0.200 |
Why?
| | Phenotype | 7 | 2019 | 3051 | 0.190 |
Why?
| | Leukodystrophy, Metachromatic | 1 | 2001 | 3 | 0.190 |
Why?
| | Cost of Illness | 1 | 2003 | 278 | 0.190 |
Why?
| | Strabismus | 1 | 2021 | 28 | 0.180 |
Why?
| | Metabolism | 1 | 2021 | 38 | 0.180 |
Why?
| | Chromosomes, Human, Pair 10 | 1 | 2000 | 18 | 0.180 |
Why?
| | Amino Acid Metabolism, Inborn Errors | 2 | 2021 | 22 | 0.180 |
Why?
| | Acyl-CoA Dehydrogenase | 3 | 2012 | 8 | 0.170 |
Why?
| | Prenatal Care | 1 | 2023 | 275 | 0.170 |
Why?
| | Cardiomyopathies | 1 | 2024 | 336 | 0.170 |
Why?
| | Double-Blind Method | 4 | 2023 | 1856 | 0.170 |
Why?
| | Hospitals, Pediatric | 1 | 2003 | 509 | 0.170 |
Why?
| | Adult | 18 | 2024 | 35299 | 0.170 |
Why?
| | Alleles | 3 | 2019 | 842 | 0.170 |
Why?
| | Orphan Drug Production | 1 | 2019 | 5 | 0.160 |
Why?
| | Registries | 4 | 2021 | 1883 | 0.160 |
Why?
| | Mental Status and Dementia Tests | 1 | 2019 | 23 | 0.160 |
Why?
| | Vitamin B 12 Deficiency | 1 | 2019 | 78 | 0.160 |
Why?
| | Attention Deficit Disorder with Hyperactivity | 1 | 2023 | 395 | 0.160 |
Why?
| | Poly-ADP-Ribose Binding Proteins | 1 | 2018 | 33 | 0.150 |
Why?
| | DNA Polymerase II | 1 | 2018 | 38 | 0.150 |
Why?
| | Polycomb Repressive Complex 2 | 1 | 2019 | 63 | 0.150 |
Why?
| | Osteochondrodysplasias | 1 | 2018 | 16 | 0.150 |
Why?
| | Sensitivity and Specificity | 3 | 2017 | 1817 | 0.150 |
Why?
| | Goldenhar Syndrome | 1 | 1998 | 3 | 0.150 |
Why?
| | Eye Abnormalities | 1 | 1998 | 11 | 0.150 |
Why?
| | Skin Abnormalities | 1 | 1998 | 12 | 0.150 |
Why?
| | Adrenal Insufficiency | 1 | 2018 | 32 | 0.150 |
Why?
| | Fetus | 1 | 2023 | 765 | 0.150 |
Why?
| | Diagnosis, Differential | 3 | 2017 | 1412 | 0.150 |
Why?
| | Fructose Intolerance | 1 | 2018 | 4 | 0.150 |
Why?
| | Fructose-Bisphosphate Aldolase | 1 | 2018 | 8 | 0.150 |
Why?
| | Exome | 1 | 2019 | 220 | 0.150 |
Why?
| | Chromosomes, Human, Pair 22 | 1 | 1998 | 41 | 0.150 |
Why?
| | Endpoint Determination | 1 | 2018 | 76 | 0.150 |
Why?
| | Urogenital Abnormalities | 1 | 2018 | 52 | 0.150 |
Why?
| | Prodrugs | 1 | 2018 | 48 | 0.150 |
Why?
| | Lipase | 1 | 2018 | 64 | 0.150 |
Why?
| | Pyruvate Dehydrogenase Complex | 1 | 2017 | 8 | 0.140 |
Why?
| | Pyruvate Dehydrogenase Complex Deficiency Disease | 1 | 2017 | 6 | 0.140 |
Why?
| | Methionyl Aminopeptidases | 1 | 2017 | 1 | 0.140 |
Why?
| | Early Termination of Clinical Trials | 1 | 2017 | 15 | 0.140 |
Why?
| | Ketones | 1 | 2017 | 47 | 0.140 |
Why?
| | Enzyme Assays | 1 | 2017 | 25 | 0.140 |
Why?
| | Intention to Treat Analysis | 1 | 2017 | 68 | 0.140 |
Why?
| | Pediatricians | 1 | 2019 | 129 | 0.140 |
Why?
| | Syndrome | 4 | 2020 | 336 | 0.140 |
Why?
| | Parents | 3 | 2020 | 1307 | 0.130 |
Why?
| | Glutaryl-CoA Dehydrogenase | 1 | 2016 | 4 | 0.130 |
Why?
| | Body Mass Index | 2 | 2017 | 2263 | 0.130 |
Why?
| | Chemical and Drug Induced Liver Injury | 1 | 2018 | 131 | 0.130 |
Why?
| | Brain Diseases, Metabolic | 1 | 2016 | 7 | 0.130 |
Why?
| | Imaging, Three-Dimensional | 1 | 2020 | 529 | 0.130 |
Why?
| | Patient Preference | 1 | 2018 | 185 | 0.130 |
Why?
| | Predictive Value of Tests | 3 | 2015 | 1938 | 0.120 |
Why?
| | Prevalence | 2 | 2012 | 2553 | 0.120 |
Why?
| | United States | 6 | 2020 | 13840 | 0.120 |
Why?
| | Cognition | 2 | 2023 | 1110 | 0.120 |
Why?
| | Indians, North American | 1 | 2001 | 599 | 0.120 |
Why?
| | Venous Thrombosis | 1 | 2017 | 176 | 0.120 |
Why?
| | Infant, Very Low Birth Weight | 1 | 2015 | 67 | 0.120 |
Why?
| | Mosaicism | 2 | 2005 | 71 | 0.110 |
Why?
| | Biomarkers | 4 | 2024 | 3893 | 0.110 |
Why?
| | Genetic Counseling | 1 | 2014 | 72 | 0.110 |
Why?
| | Mitochondrial Encephalomyopathies | 1 | 2013 | 8 | 0.110 |
Why?
| | Hepatic Encephalopathy | 1 | 2013 | 19 | 0.110 |
Why?
| | Fibroblasts | 2 | 2017 | 937 | 0.110 |
Why?
| | Genotype | 1 | 2019 | 1830 | 0.110 |
Why?
| | Cohort Studies | 3 | 2024 | 5402 | 0.100 |
Why?
| | Fetal Growth Retardation | 1 | 2018 | 543 | 0.100 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2017 | 1951 | 0.100 |
Why?
| | Rape | 1 | 2013 | 39 | 0.100 |
Why?
| | Drug Substitution | 1 | 2013 | 51 | 0.100 |
Why?
| | Ubiquinone | 1 | 2012 | 28 | 0.100 |
Why?
| | Siblings | 1 | 2013 | 215 | 0.100 |
Why?
| | Weight Loss | 1 | 2017 | 727 | 0.100 |
Why?
| | Intellectual Disability | 3 | 2019 | 149 | 0.090 |
Why?
| | Mitochondrial Diseases | 1 | 2012 | 90 | 0.090 |
Why?
| | Carnitine | 2 | 2003 | 76 | 0.090 |
Why?
| | Severity of Illness Index | 2 | 2017 | 2719 | 0.090 |
Why?
| | Caregivers | 1 | 2018 | 813 | 0.090 |
Why?
| | Urinary Tract | 1 | 1991 | 38 | 0.090 |
Why?
| | Self Report | 1 | 2015 | 797 | 0.090 |
Why?
| | Chromosomes, Human, Pair 19 | 1 | 2010 | 23 | 0.090 |
Why?
| | Infant, Premature | 1 | 2015 | 538 | 0.090 |
Why?
| | 5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase | 2 | 2021 | 17 | 0.090 |
Why?
| | Ectodermal Dysplasia | 1 | 2010 | 16 | 0.090 |
Why?
| | Heart Defects, Congenital | 3 | 2010 | 750 | 0.090 |
Why?
| | Homocysteine | 2 | 2021 | 149 | 0.090 |
Why?
| | Diaphragm | 1 | 2010 | 43 | 0.090 |
Why?
| | Surveys and Questionnaires | 4 | 2022 | 5371 | 0.090 |
Why?
| | Diseases in Twins | 1 | 1991 | 176 | 0.080 |
Why?
| | Vaginal Diseases | 1 | 2010 | 22 | 0.080 |
Why?
| | Algorithms | 1 | 2017 | 1614 | 0.080 |
Why?
| | Risk | 1 | 2012 | 853 | 0.080 |
Why?
| | Chromosome Banding | 2 | 2010 | 21 | 0.080 |
Why?
| | Mental Disorders | 1 | 1998 | 1007 | 0.080 |
Why?
| | Middle Aged | 10 | 2021 | 30921 | 0.080 |
Why?
| | Liver | 3 | 2013 | 1827 | 0.080 |
Why?
| | Abdomen | 1 | 2010 | 118 | 0.080 |
Why?
| | Glycogen Storage Disease Type II | 1 | 2009 | 7 | 0.080 |
Why?
| | alpha-Glucosidases | 1 | 2009 | 12 | 0.080 |
Why?
| | Cysts | 1 | 2010 | 108 | 0.080 |
Why?
| | Cytomegalovirus Infections | 1 | 2010 | 186 | 0.080 |
Why?
| | Follow-Up Studies | 4 | 2021 | 4874 | 0.070 |
Why?
| | Ultrasonography, Prenatal | 1 | 2010 | 270 | 0.070 |
Why?
| | Overweight | 1 | 2012 | 523 | 0.070 |
Why?
| | Gene Frequency | 2 | 2016 | 504 | 0.070 |
Why?
| | Iduronate Sulfatase | 1 | 2006 | 1 | 0.070 |
Why?
| | Mucopolysaccharidosis II | 1 | 2006 | 3 | 0.070 |
Why?
| | Cooperative Behavior | 1 | 2010 | 424 | 0.070 |
Why?
| | Respiratory Insufficiency | 1 | 2010 | 311 | 0.070 |
Why?
| | Time Factors | 2 | 2015 | 6505 | 0.070 |
Why?
| | Cross-Over Studies | 3 | 2014 | 509 | 0.070 |
Why?
| | Sex Factors | 1 | 2012 | 1951 | 0.070 |
Why?
| | In Situ Hybridization, Fluorescence | 2 | 2005 | 313 | 0.060 |
Why?
| | Brain | 1 | 1998 | 2624 | 0.060 |
Why?
| | Muscle, Skeletal | 2 | 2013 | 1624 | 0.060 |
Why?
| | Echocardiography | 2 | 2024 | 624 | 0.060 |
Why?
| | Spectrometry, Mass, Electrospray Ionization | 1 | 2006 | 167 | 0.060 |
Why?
| | Retrospective Studies | 3 | 2022 | 14471 | 0.060 |
Why?
| | Karyotyping | 1 | 2005 | 107 | 0.060 |
Why?
| | Fragile X Syndrome | 1 | 2005 | 76 | 0.060 |
Why?
| | Chromosome Disorders | 1 | 2005 | 40 | 0.060 |
Why?
| | Diet | 1 | 2012 | 1204 | 0.060 |
Why?
| | Disease Management | 2 | 2019 | 584 | 0.060 |
Why?
| | Fatal Outcome | 2 | 2010 | 301 | 0.060 |
Why?
| | Anxiety | 2 | 2023 | 952 | 0.060 |
Why?
| | Microcephaly | 1 | 2005 | 87 | 0.060 |
Why?
| | Radiography | 2 | 2010 | 795 | 0.060 |
Why?
| | Pregnancy | 4 | 2023 | 6373 | 0.050 |
Why?
| | Neuropsychological Tests | 3 | 2019 | 1005 | 0.050 |
Why?
| | Gene Deletion | 1 | 2005 | 370 | 0.050 |
Why?
| | X Chromosome | 2 | 2000 | 51 | 0.050 |
Why?
| | Lymphocytes | 3 | 2017 | 368 | 0.050 |
Why?
| | Heterozygote | 2 | 2001 | 269 | 0.050 |
Why?
| | Quality of Life | 1 | 2015 | 2688 | 0.050 |
Why?
| | Hyperhomocysteinemia | 1 | 2003 | 27 | 0.050 |
Why?
| | Food, Fortified | 1 | 2003 | 37 | 0.050 |
Why?
| | Carbon-Carbon Ligases | 1 | 2003 | 2 | 0.050 |
Why?
| | Drug Combinations | 1 | 2024 | 324 | 0.050 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 2 | 2017 | 252 | 0.050 |
Why?
| | Pedigree | 2 | 2001 | 485 | 0.050 |
Why?
| | Cough | 2 | 2017 | 115 | 0.050 |
Why?
| | Oxytocin | 1 | 2023 | 48 | 0.050 |
Why?
| | Infant Food | 1 | 2003 | 65 | 0.050 |
Why?
| | Granulocyte Colony-Stimulating Factor | 1 | 2022 | 72 | 0.050 |
Why?
| | Glucosides | 1 | 2022 | 38 | 0.050 |
Why?
| | Models, Genetic | 1 | 2005 | 593 | 0.050 |
Why?
| | RNA-Binding Proteins | 1 | 2005 | 389 | 0.050 |
Why?
| | Developmental Disabilities | 1 | 2005 | 259 | 0.050 |
Why?
| | Workflow | 1 | 2023 | 154 | 0.050 |
Why?
| | Benzhydryl Compounds | 1 | 2022 | 66 | 0.050 |
Why?
| | Founder Effect | 1 | 2001 | 12 | 0.050 |
Why?
| | Homozygote | 2 | 2018 | 193 | 0.050 |
Why?
| | History, 19th Century | 1 | 2001 | 57 | 0.050 |
Why?
| | Nerve Tissue Proteins | 1 | 2005 | 570 | 0.050 |
Why?
| | United States Indian Health Service | 1 | 2001 | 42 | 0.050 |
Why?
| | Diet, Ketogenic | 1 | 2021 | 35 | 0.050 |
Why?
| | Hand Deformities, Congenital | 1 | 2000 | 7 | 0.040 |
Why?
| | Ribosomal Protein S6 Kinases | 1 | 2000 | 21 | 0.040 |
Why?
| | Warfare | 1 | 2001 | 63 | 0.040 |
Why?
| | Facies | 1 | 2000 | 21 | 0.040 |
Why?
| | Administration, Intravenous | 1 | 2021 | 137 | 0.040 |
Why?
| | Betaine | 1 | 2000 | 72 | 0.040 |
Why?
| | Early Diagnosis | 1 | 2021 | 234 | 0.040 |
Why?
| | History, 20th Century | 1 | 2001 | 288 | 0.040 |
Why?
| | Methyltransferases | 1 | 2000 | 70 | 0.040 |
Why?
| | Vitamins | 1 | 2021 | 174 | 0.040 |
Why?
| | Nucleocytoplasmic Transport Proteins | 1 | 2019 | 7 | 0.040 |
Why?
| | Cross-Sectional Studies | 2 | 2021 | 5045 | 0.040 |
Why?
| | Public-Private Sector Partnerships | 1 | 2019 | 42 | 0.040 |
Why?
| | Mutation, Missense | 1 | 2001 | 315 | 0.040 |
Why?
| | Angelman Syndrome | 1 | 1999 | 11 | 0.040 |
Why?
| | Cell Line | 1 | 2005 | 2741 | 0.040 |
Why?
| | Ornithine Carbamoyltransferase Deficiency Disease | 1 | 2019 | 6 | 0.040 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p57 | 1 | 2018 | 5 | 0.040 |
Why?
| | Age of Onset | 1 | 2020 | 495 | 0.040 |
Why?
| | Adrenoleukodystrophy | 1 | 1999 | 9 | 0.040 |
Why?
| | Genomic Imprinting | 1 | 1999 | 33 | 0.040 |
Why?
| | Incidence | 2 | 2021 | 2638 | 0.040 |
Why?
| | National Institutes of Health (U.S.) | 1 | 2019 | 122 | 0.040 |
Why?
| | MAP Kinase Signaling System | 1 | 2000 | 307 | 0.040 |
Why?
| | Urea | 1 | 2019 | 75 | 0.040 |
Why?
| | Attention Deficit and Disruptive Behavior Disorders | 1 | 1999 | 61 | 0.040 |
Why?
| | Nutritional Status | 1 | 2021 | 326 | 0.040 |
Why?
| | Executive Function | 1 | 2023 | 424 | 0.040 |
Why?
| | Delayed Diagnosis | 1 | 2019 | 79 | 0.040 |
Why?
| | Length of Stay | 1 | 2003 | 1119 | 0.040 |
Why?
| | Canada | 1 | 2019 | 346 | 0.040 |
Why?
| | Drug Industry | 1 | 2019 | 106 | 0.040 |
Why?
| | Cleft Lip | 1 | 1998 | 44 | 0.040 |
Why?
| | Europe | 1 | 2019 | 360 | 0.040 |
Why?
| | North America | 1 | 2019 | 290 | 0.040 |
Why?
| | Pyruvate Dehydrogenase (Lipoamide) | 1 | 2017 | 10 | 0.040 |
Why?
| | Cleft Palate | 1 | 1998 | 58 | 0.040 |
Why?
| | Proteomics | 1 | 2024 | 1018 | 0.040 |
Why?
| | Mice, Mutant Strains | 1 | 1997 | 293 | 0.030 |
Why?
| | Skull | 1 | 1998 | 129 | 0.030 |
Why?
| | Nitrogen | 1 | 2018 | 168 | 0.030 |
Why?
| | Lipids | 1 | 2021 | 621 | 0.030 |
Why?
| | Biochemistry | 1 | 2017 | 38 | 0.030 |
Why?
| | DNA Replication | 1 | 2018 | 225 | 0.030 |
Why?
| | Recombinant Proteins | 3 | 2006 | 1291 | 0.030 |
Why?
| | Renal Dialysis | 1 | 2020 | 423 | 0.030 |
Why?
| | Child Behavior Disorders | 1 | 1998 | 134 | 0.030 |
Why?
| | Global Health | 1 | 2019 | 330 | 0.030 |
Why?
| | Glutarates | 1 | 2016 | 8 | 0.030 |
Why?
| | Neoplasm Proteins | 1 | 2019 | 420 | 0.030 |
Why?
| | Prospective Studies | 2 | 2019 | 7069 | 0.030 |
Why?
| | Cocaine | 1 | 1998 | 148 | 0.030 |
Why?
| | Fever | 1 | 2017 | 297 | 0.030 |
Why?
| | Glucose | 1 | 2021 | 983 | 0.030 |
Why?
| | Child Behavior | 1 | 1998 | 235 | 0.030 |
Why?
| | Computational Biology | 1 | 2019 | 597 | 0.030 |
Why?
| | Pandemics | 1 | 2023 | 1477 | 0.030 |
Why?
| | Cognition Disorders | 1 | 1999 | 498 | 0.030 |
Why?
| | North Carolina | 2 | 2006 | 98 | 0.030 |
Why?
| | Fasting | 1 | 2015 | 264 | 0.030 |
Why?
| | Primary Health Care | 1 | 2004 | 1641 | 0.030 |
Why?
| | Tandem Mass Spectrometry | 1 | 2016 | 456 | 0.030 |
Why?
| | Molecular Sequence Data | 3 | 2005 | 2822 | 0.030 |
Why?
| | Immunoglobulin G | 2 | 2009 | 844 | 0.030 |
Why?
| | Pregnancy Complications | 1 | 1998 | 491 | 0.030 |
Why?
| | Treatment Outcome | 2 | 2023 | 10162 | 0.030 |
Why?
| | Enzyme Stability | 2 | 2004 | 67 | 0.030 |
Why?
| | Pediatrics | 1 | 2020 | 1050 | 0.030 |
Why?
| | Biomarkers, Pharmacological | 1 | 2012 | 26 | 0.020 |
Why?
| | DNA Mutational Analysis | 2 | 2005 | 385 | 0.020 |
Why?
| | Mutagenesis, Site-Directed | 2 | 2004 | 359 | 0.020 |
Why?
| | Alcohol Drinking | 1 | 1998 | 758 | 0.020 |
Why?
| | Liver Transplantation | 1 | 2019 | 800 | 0.020 |
Why?
| | Transcription Factors | 1 | 2019 | 1635 | 0.020 |
Why?
| | Blood Grouping and Crossmatching | 1 | 1991 | 14 | 0.020 |
Why?
| | DNA | 2 | 2010 | 1394 | 0.020 |
Why?
| | Age Factors | 1 | 2018 | 3122 | 0.020 |
Why?
| | Physical Chromosome Mapping | 1 | 2010 | 17 | 0.020 |
Why?
| | Chromosomes, Artificial, Bacterial | 1 | 2010 | 17 | 0.020 |
Why?
| | Chromosome Breakage | 1 | 2010 | 21 | 0.020 |
Why?
| | Comparative Genomic Hybridization | 1 | 2010 | 32 | 0.020 |
Why?
| | Muscle Hypotonia | 1 | 2010 | 32 | 0.020 |
Why?
| | Twins, Monozygotic | 1 | 1991 | 209 | 0.020 |
Why?
| | Colpotomy | 1 | 2010 | 2 | 0.020 |
Why?
| | Drug Administration Schedule | 1 | 2012 | 764 | 0.020 |
Why?
| | Interinstitutional Relations | 1 | 2010 | 54 | 0.020 |
Why?
| | HLA Antigens | 1 | 1991 | 234 | 0.020 |
Why?
| | Cells, Cultured | 1 | 2017 | 4017 | 0.020 |
Why?
| | Prognosis | 1 | 2018 | 3780 | 0.020 |
Why?
| | Pilot Projects | 2 | 2006 | 1568 | 0.020 |
Why?
| | Glycogen | 1 | 2009 | 55 | 0.020 |
Why?
| | Tracheostomy | 1 | 2010 | 120 | 0.020 |
Why?
| | Escherichia coli | 2 | 2004 | 771 | 0.020 |
Why?
| | Body Height | 1 | 2009 | 193 | 0.020 |
Why?
| | Vagina | 1 | 2010 | 175 | 0.020 |
Why?
| | Aged | 2 | 2018 | 21974 | 0.020 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2013 | 1358 | 0.020 |
Why?
| | Skin Diseases | 1 | 2009 | 141 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2018 | 7057 | 0.020 |
Why?
| | Kaplan-Meier Estimate | 1 | 2009 | 856 | 0.020 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2009 | 820 | 0.020 |
Why?
| | Glycosaminoglycans | 1 | 2006 | 84 | 0.020 |
Why?
| | Biomedical Research | 1 | 2012 | 633 | 0.020 |
Why?
| | Research Design | 1 | 2012 | 1036 | 0.020 |
Why?
| | False Negative Reactions | 1 | 2006 | 51 | 0.020 |
Why?
| | Respiration, Artificial | 1 | 2010 | 604 | 0.020 |
Why?
| | Blood Specimen Collection | 1 | 2006 | 34 | 0.020 |
Why?
| | Joints | 1 | 2006 | 100 | 0.020 |
Why?
| | Infusions, Intravenous | 1 | 2006 | 394 | 0.020 |
Why?
| | Blotting, Southern | 1 | 2005 | 68 | 0.020 |
Why?
| | Fragile X Mental Retardation Protein | 1 | 2005 | 59 | 0.010 |
Why?
| | Myristic Acid | 1 | 2004 | 10 | 0.010 |
Why?
| | Respiratory Function Tests | 1 | 2006 | 580 | 0.010 |
Why?
| | Safety | 1 | 2006 | 328 | 0.010 |
Why?
| | Spleen | 1 | 2006 | 509 | 0.010 |
Why?
| | Histidine | 1 | 2004 | 58 | 0.010 |
Why?
| | Body Weight | 1 | 2009 | 933 | 0.010 |
Why?
| | Circular Dichroism | 1 | 2004 | 148 | 0.010 |
Why?
| | Mitochondria, Liver | 1 | 2004 | 73 | 0.010 |
Why?
| | Antineoplastic Agents | 1 | 2015 | 2042 | 0.010 |
Why?
| | Tyrosine | 1 | 2004 | 218 | 0.010 |
Why?
| | Amino Acid Substitution | 1 | 2004 | 281 | 0.010 |
Why?
| | Structure-Activity Relationship | 1 | 2004 | 539 | 0.010 |
Why?
| | Acids | 1 | 2003 | 16 | 0.010 |
Why?
| | Fatty Acids | 1 | 2006 | 417 | 0.010 |
Why?
| | Brain Edema | 1 | 2003 | 60 | 0.010 |
Why?
| | Longitudinal Studies | 1 | 2010 | 2710 | 0.010 |
Why?
| | Glutamic Acid | 1 | 2004 | 228 | 0.010 |
Why?
| | Lysine | 1 | 2004 | 285 | 0.010 |
Why?
| | Chaperonin 10 | 1 | 2001 | 2 | 0.010 |
Why?
| | Base Sequence | 1 | 2005 | 2137 | 0.010 |
Why?
| | Infant Nutritional Physiological Phenomena | 1 | 2003 | 137 | 0.010 |
Why?
| | Chaperonin 60 | 1 | 2001 | 14 | 0.010 |
Why?
| | Prion Proteins | 1 | 2000 | 4 | 0.010 |
Why?
| | Chromosomes, Human, Pair 5 | 1 | 2000 | 29 | 0.010 |
Why?
| | Betaine-Homocysteine S-Methyltransferase | 1 | 2000 | 11 | 0.010 |
Why?
| | Oxidation-Reduction | 1 | 2004 | 1003 | 0.010 |
Why?
| | Two-Hybrid System Techniques | 1 | 2000 | 56 | 0.010 |
Why?
| | Prions | 1 | 2000 | 46 | 0.010 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2000 | 369 | 0.010 |
Why?
| | Amyloid | 1 | 2000 | 84 | 0.010 |
Why?
| | Protein Precursors | 1 | 2000 | 127 | 0.010 |
Why?
| | Exons | 1 | 2001 | 339 | 0.010 |
Why?
| | Protein Folding | 1 | 2001 | 266 | 0.010 |
Why?
| | Chromosome Mapping | 1 | 2000 | 504 | 0.010 |
Why?
| | Haplotypes | 1 | 2001 | 471 | 0.010 |
Why?
| | Models, Molecular | 1 | 2004 | 1484 | 0.010 |
Why?
| | Wechsler Scales | 1 | 1999 | 53 | 0.010 |
Why?
| | Neoplasms | 1 | 2013 | 2463 | 0.010 |
Why?
| | Sequence Deletion | 1 | 1999 | 178 | 0.010 |
Why?
| | Genetic Linkage | 1 | 1999 | 299 | 0.010 |
Why?
| | Temperature | 1 | 2001 | 632 | 0.010 |
Why?
| | Sequence Analysis, DNA | 1 | 2000 | 775 | 0.010 |
Why?
| | Amino Acid Sequence | 1 | 2000 | 2044 | 0.010 |
Why?
| | Social Behavior | 1 | 1999 | 288 | 0.010 |
Why?
| | Rats | 1 | 2004 | 5246 | 0.010 |
Why?
| | Polymerase Chain Reaction | 1 | 1999 | 1027 | 0.010 |
Why?
| | Animals | 3 | 2004 | 34647 | 0.010 |
Why?
| | DNA Methylation | 1 | 1999 | 607 | 0.010 |
Why?
| | Reproducibility of Results | 1 | 2001 | 3021 | 0.010 |
Why?
| | Genetic Variation | 1 | 1997 | 935 | 0.010 |
Why?
| | Mice | 2 | 2000 | 16620 | 0.010 |
Why?
| | Disease Progression | 1 | 1999 | 2604 | 0.010 |
Why?
| | Magnetic Resonance Imaging | 1 | 2003 | 3387 | 0.010 |
Why?
|
|
McCandless's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|